Search research articles
Contact Us
Filters
Showing results (281-290 of 686) with videos related to
Page
of 69
Sort By:
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
Timothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Journal of the American Medical Informatics Association : JAMIA
|
April 24, 2016
Automated identification of molecular effects of drugs (AIMED)
Safa Fathiamini, Amber M Johnson, Jia Zeng, et al.
Journal of Cutaneous Pathology
|
July 19, 2018
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor
Krishna Arudra, Ravi Patel, Michael T Tetzlaff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
David S Hong, Razelle Kurzrock, Yun Oh, et al.
Annals of Surgery
|
August 24, 2006
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer
Judy C Boughey, Florentia Peintinger, Funda Meric-Bernstam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer
Leonel F Hernandez-Aya, Mariana Chavez-Macgregor, Xiudong Lei, et al.
Annals of Surgical Oncology
|
August 18, 2004
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy
Jeannie Shen, Vicente Valero, Thomas A Buchholz, et al.
Cancer Chemotherapy and Pharmacology
|
June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Clinical Breast Cancer
|
December 3, 2014
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes
Napa Parinyanitikul, Xiudong Lei, Mariana Chavez-MacGregor, et al.
Endocrine-Related Cancer
|
April 23, 2015
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors
Arvind Dasari, Alexandria Phan, Sanjay Gupta, et al.
Page
of 69
Search research articles
Search
Showing results (281-290 of 686) with videos related to
Sort By:
Page
of 69
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
Timothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Journal of the American Medical Informatics Association : JAMIA
|
April 24, 2016
Automated identification of molecular effects of drugs (AIMED)
Safa Fathiamini, Amber M Johnson, Jia Zeng, et al.
Journal of Cutaneous Pathology
|
July 19, 2018
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor
Krishna Arudra, Ravi Patel, Michael T Tetzlaff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
David S Hong, Razelle Kurzrock, Yun Oh, et al.
Annals of Surgery
|
August 24, 2006
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer
Judy C Boughey, Florentia Peintinger, Funda Meric-Bernstam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer
Leonel F Hernandez-Aya, Mariana Chavez-Macgregor, Xiudong Lei, et al.
Annals of Surgical Oncology
|
August 18, 2004
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy
Jeannie Shen, Vicente Valero, Thomas A Buchholz, et al.
Cancer Chemotherapy and Pharmacology
|
June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Clinical Breast Cancer
|
December 3, 2014
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes
Napa Parinyanitikul, Xiudong Lei, Mariana Chavez-MacGregor, et al.
Endocrine-Related Cancer
|
April 23, 2015
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors
Arvind Dasari, Alexandria Phan, Sanjay Gupta, et al.
Page
of 69